EP3749321A4 - Antifolates gamma-polyglutamatés et utilisations associées - Google Patents
Antifolates gamma-polyglutamatés et utilisations associées Download PDFInfo
- Publication number
- EP3749321A4 EP3749321A4 EP19752055.4A EP19752055A EP3749321A4 EP 3749321 A4 EP3749321 A4 EP 3749321A4 EP 19752055 A EP19752055 A EP 19752055A EP 3749321 A4 EP3749321 A4 EP 3749321A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- gamma
- polyglutamated antifolates
- polyglutamated
- antifolates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627733P | 2018-02-07 | 2018-02-07 | |
| US201862627732P | 2018-02-07 | 2018-02-07 | |
| US201862630751P | 2018-02-14 | 2018-02-14 | |
| US201862630652P | 2018-02-14 | 2018-02-14 | |
| US201862630613P | 2018-02-14 | 2018-02-14 | |
| US201862630824P | 2018-02-14 | 2018-02-14 | |
| US201862630625P | 2018-02-14 | 2018-02-14 | |
| US201862630620P | 2018-02-14 | 2018-02-14 | |
| US201862636289P | 2018-02-28 | 2018-02-28 | |
| US201862662372P | 2018-04-25 | 2018-04-25 | |
| US201862702774P | 2018-07-24 | 2018-07-24 | |
| US201862702779P | 2018-07-24 | 2018-07-24 | |
| US201862764945P | 2018-08-17 | 2018-08-17 | |
| US201862764951P | 2018-08-17 | 2018-08-17 | |
| PCT/US2019/017004 WO2019157148A1 (fr) | 2018-02-07 | 2019-02-07 | Antifolates gamma-polyglutamatés et utilisations associées |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3749321A1 EP3749321A1 (fr) | 2020-12-16 |
| EP3749321A4 true EP3749321A4 (fr) | 2022-03-09 |
Family
ID=67548055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19752055.4A Pending EP3749321A4 (fr) | 2018-02-07 | 2019-02-07 | Antifolates gamma-polyglutamatés et utilisations associées |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3749321A4 (fr) |
| JP (3) | JP7490240B2 (fr) |
| CN (1) | CN111936147A (fr) |
| CA (1) | CA3090505A1 (fr) |
| WO (1) | WO2019157148A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3496757A4 (fr) | 2016-08-12 | 2020-04-15 | L.E.A.F Holdings Group LLC | Antifolates de polyglutamates et leurs utilisations. |
| US20180236098A1 (en) | 2016-08-12 | 2018-08-23 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| EP3749317A4 (fr) | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | Pémétrexed alpha-polyglutamaté et utilisations associées |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| EP3749318A4 (fr) | 2018-02-07 | 2022-07-06 | L.E.A.F Holdings Group LLC | Raltitrexed gamma-polyglutamaté et utilisations associées |
| US12246015B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| US12310966B2 (en) | 2018-02-07 | 2025-05-27 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| WO2019157145A1 (fr) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Compositions de pémétrexed polyglutamaté gamma et leurs utilisations |
| CA3090506A1 (fr) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Tetrahydrofolates alpha polyglutames et leurs utilisations |
| JP7491573B2 (ja) | 2018-02-07 | 2024-05-28 | エル.イー.エー.エフ. ホールディングス グループ エルエルシー | アルファポリグルタミン酸化メトトレキセートおよびその使用 |
| US12246019B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| US11730738B2 (en) | 2018-02-07 | 2023-08-22 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| US12076402B2 (en) | 2018-02-07 | 2024-09-03 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
| CA3090989A1 (fr) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Methotrexate gamma polyglutamique et ses utilisations |
| CA3090753A1 (fr) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Pralatrexate gamma-polyglutamate et utilisations associees |
| EP3752158A4 (fr) * | 2018-02-14 | 2022-03-09 | L.E.A.F Holdings Group LLC | Aminoptérine gamma polyglutamique et ses utilisations |
| WO2019160735A1 (fr) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Tétrahydrofolates gamma polyglutamiques et leurs utilisations |
| WO2019160734A1 (fr) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Lométrexol gamma polyglutamique et ses utilisations |
| CA3149914A1 (fr) * | 2019-08-06 | 2021-02-11 | L.E.A.F. Holdings Group Llc | Procedes de preparation d'antifolates polyglutamiques et leurs utilisations |
Citations (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006029385A2 (fr) * | 2004-09-08 | 2006-03-16 | Chelsea Therapeutics, Inc. | Antifoliques metaboliquement inertes utiles dans le traitement des maladies liees a la proliferation cellulaire anormale et a une inflammation |
| WO2006074416A1 (fr) * | 2005-01-07 | 2006-07-13 | Health Research Inc. | 5-amino-4-imidazolecarboxamide riboside et sa nucléobase en tant qu'agents amplificateurs du transport et du métabolisme d'antifolates |
| WO2016025882A2 (fr) * | 2014-08-14 | 2016-02-18 | L.E.A.F Holdings Group Llc. | Médicament à affinité encapsulé dans un liposome |
| WO2018031979A1 (fr) * | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Antifolates alpha et gamma-d de polyglutamates et leurs utilisations. |
| WO2019094648A1 (fr) * | 2017-11-08 | 2019-05-16 | L.E.A.F. Holdings Group Llc | Complexes de platine et leurs utilisations |
| WO2019157146A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Antifolates alpha-polyglutamatés et utilisations associées |
| WO2019157125A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Méthotrexate alpha-polyglutamaté et utilisations associées |
| WO2019157121A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Lométrexol alpha-polyglutamaté et utilisations associées |
| WO2019157140A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Raltitrexed gamma-polyglutamaté et utilisations associées |
| WO2019157129A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Pralatrexate alpha-polyglutamaté et utilisations associées |
| WO2019157123A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Aminoptérine alpha-polyglutamatée et utilisations associées |
| WO2019157138A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Pémétrexed alpha-polyglutamaté et utilisations associées |
| WO2019157145A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Compositions de pémétrexed polyglutamaté gamma et leurs utilisations |
| WO2019157133A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Raltitrexed alpha-polyglutamaté et utilisations associées |
| WO2019157120A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Tétrahydrofolates alpha polyglutamés et leurs utilisations |
| WO2019160732A1 (fr) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Aminoptérine gamma polyglutamique et ses utilisations |
| WO2019160733A1 (fr) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Méthotrexate gamma polyglutamique et ses utilisations |
| WO2019160734A1 (fr) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Lométrexol gamma polyglutamique et ses utilisations |
| WO2019160736A1 (fr) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Pralatrexate gamma-polyglutamaté et utilisations associées |
| WO2019160735A1 (fr) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Tétrahydrofolates gamma polyglutamiques et leurs utilisations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6569432B1 (en) * | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
| WO2001053331A2 (fr) * | 2000-01-24 | 2001-07-26 | Adherex Technologies, Inc. | Modulateurs peptidomimetiques de l'adhesion cellulaire |
| US7612071B2 (en) * | 2004-03-12 | 2009-11-03 | Syntrix Biosystems, Inc. | Compositions and methods employing aminopterin |
| US8073630B2 (en) * | 2006-08-30 | 2011-12-06 | Exagen Diagnostics, Inc. | Pharacogenetic method for prediction of the efficacy of methotrexate monotherapy in recent-onset arthritis |
| BRPI0722053A2 (pt) * | 2006-12-29 | 2018-04-17 | Tracon Pharmaceuticals Inc | método para o tratamento de câncer, formulação anticâncer, método de uso da formulação, e, uso de metoxiamina |
| KR20090113295A (ko) * | 2007-01-19 | 2009-10-29 | 첼시 쎄라퓨틱스, 인코포레이티드 | 새로운 유형의 항엽산제 |
| US8609642B2 (en) * | 2009-06-03 | 2013-12-17 | Ex-Tek, Llc | Skin treatment compositions |
| US9770414B2 (en) * | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
| PL226015B1 (pl) * | 2011-03-03 | 2017-06-30 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną | Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna |
| CN103040748B (zh) * | 2012-12-18 | 2014-07-02 | 海南圣欣医药科技有限公司 | 一种培美曲塞二钠脂质体注射剂 |
| US20180236098A1 (en) * | 2016-08-12 | 2018-08-23 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| EP3496757A4 (fr) * | 2016-08-12 | 2020-04-15 | L.E.A.F Holdings Group LLC | Antifolates de polyglutamates et leurs utilisations. |
-
2019
- 2019-02-07 EP EP19752055.4A patent/EP3749321A4/fr active Pending
- 2019-02-07 CA CA3090505A patent/CA3090505A1/fr active Pending
- 2019-02-07 CN CN201980024669.5A patent/CN111936147A/zh active Pending
- 2019-02-07 WO PCT/US2019/017004 patent/WO2019157148A1/fr not_active Ceased
- 2019-02-07 JP JP2020542733A patent/JP7490240B2/ja active Active
-
2024
- 2024-05-08 JP JP2024075778A patent/JP7676063B2/ja active Active
-
2025
- 2025-04-22 JP JP2025070872A patent/JP2025105775A/ja active Pending
Patent Citations (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006029385A2 (fr) * | 2004-09-08 | 2006-03-16 | Chelsea Therapeutics, Inc. | Antifoliques metaboliquement inertes utiles dans le traitement des maladies liees a la proliferation cellulaire anormale et a une inflammation |
| WO2006074416A1 (fr) * | 2005-01-07 | 2006-07-13 | Health Research Inc. | 5-amino-4-imidazolecarboxamide riboside et sa nucléobase en tant qu'agents amplificateurs du transport et du métabolisme d'antifolates |
| WO2016025882A2 (fr) * | 2014-08-14 | 2016-02-18 | L.E.A.F Holdings Group Llc. | Médicament à affinité encapsulé dans un liposome |
| WO2018031979A1 (fr) * | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Antifolates alpha et gamma-d de polyglutamates et leurs utilisations. |
| WO2018031980A1 (fr) * | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Antifolates de polyglutamates et leurs utilisations. |
| WO2019094648A1 (fr) * | 2017-11-08 | 2019-05-16 | L.E.A.F. Holdings Group Llc | Complexes de platine et leurs utilisations |
| WO2019157146A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Antifolates alpha-polyglutamatés et utilisations associées |
| WO2019157125A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Méthotrexate alpha-polyglutamaté et utilisations associées |
| WO2019157121A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Lométrexol alpha-polyglutamaté et utilisations associées |
| WO2019157140A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Raltitrexed gamma-polyglutamaté et utilisations associées |
| WO2019157129A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Pralatrexate alpha-polyglutamaté et utilisations associées |
| WO2019157123A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Aminoptérine alpha-polyglutamatée et utilisations associées |
| WO2019157138A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Pémétrexed alpha-polyglutamaté et utilisations associées |
| WO2019157145A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Compositions de pémétrexed polyglutamaté gamma et leurs utilisations |
| WO2019157133A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Raltitrexed alpha-polyglutamaté et utilisations associées |
| WO2019157120A1 (fr) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Tétrahydrofolates alpha polyglutamés et leurs utilisations |
| WO2019160732A1 (fr) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Aminoptérine gamma polyglutamique et ses utilisations |
| WO2019160733A1 (fr) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Méthotrexate gamma polyglutamique et ses utilisations |
| WO2019160734A1 (fr) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Lométrexol gamma polyglutamique et ses utilisations |
| WO2019160736A1 (fr) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Pralatrexate gamma-polyglutamaté et utilisations associées |
| WO2019160735A1 (fr) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Tétrahydrofolates gamma polyglutamiques et leurs utilisations |
Non-Patent Citations (4)
| Title |
|---|
| ALEXIS F ET AL: "Nanoparticle technologies for cancer therapy", 1 January 2010, DRUG DELIVERY IN: HANDBOOK OF EXPERIMENTAL PHARMACOLOGY; ISSN 0171-2004; VOL. 197; [HANDBOOK OF EXPERIMENTAL PHARMACOLOGY; ISSN 0171-2004; VOL. 197], SPRINGER, DE, PAGE(S) 55 - 86, ISBN: 978-3-642-00476-6, XP008182266 * |
| FIEHN C: "The future of methotrexate therapy and other folate inhibitors", ZEITSCHRIFT F�R RHEUMATOLOGIE, SPRINGER, DE, vol. 70, no. 2, 27 January 2011 (2011-01-27), pages 129 - 134, XP036030662, ISSN: 0340-1855, [retrieved on 20110127], DOI: 10.1007/S00393-010-0688-Z * |
| PIPER J R ET AL: "Syntheses of .alpha.- and .gamma.-substituted Amides, Peptides, and Esters of Methotrexate and Their Evaluation as Inhibitors of Folate Metabolism", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 25, no. 2, 1 January 1982 (1982-01-01), pages 182 - 187, XP002413066, ISSN: 0022-2623, DOI: 10.1021/JM00344A018 * |
| See also references of WO2019157148A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021513533A (ja) | 2021-05-27 |
| JP7676063B2 (ja) | 2025-05-14 |
| CA3090505A1 (fr) | 2019-08-15 |
| CN111936147A (zh) | 2020-11-13 |
| JP2025105775A (ja) | 2025-07-10 |
| JP2024097894A (ja) | 2024-07-19 |
| EP3749321A1 (fr) | 2020-12-16 |
| WO2019157148A1 (fr) | 2019-08-15 |
| JP7490240B2 (ja) | 2024-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3749313A4 (fr) | Antifolates alpha-polyglutamatés et utilisations associées | |
| EP3749321A4 (fr) | Antifolates gamma-polyglutamatés et utilisations associées | |
| EP3496756A4 (fr) | Antifolates alpha et gamma-d de polyglutamates et leurs utilisations. | |
| EP3684365A4 (fr) | Agents de dégradation des protéines et utilisations de ces derniers | |
| EP3749319A4 (fr) | Tétrahydrofolates alpha polyglutamés et leurs utilisations | |
| EP3829663A4 (fr) | Échafaudages implantables et utilisations associées | |
| EP3759143A4 (fr) | Anticorps anti-tigit et leurs utilisations | |
| EP3740224A4 (fr) | Anticorps anti-lilrb et leurs utilisations | |
| EP3755335A4 (fr) | Tétrahydrofolates gamma polyglutamiques et leurs utilisations | |
| EP3544618A4 (fr) | Expansion cellulaire modifiée et ses utilisations | |
| LT3448386T (lt) | Izochinolin-3-ilo karboksamidai ir jų gamyba bei naudojimas | |
| EP3576765A4 (fr) | Interféron d'ingénierie ciblé et utilisations de ce dernier | |
| EP3411412A4 (fr) | Technologie fit-immunoglobuline et ses utilisations | |
| EP3781318A4 (fr) | Émulsifiants et leurs utilisations | |
| EP3893945A4 (fr) | Esters cromoglycique et leurs utilisations | |
| EP3634178A4 (fr) | Agencement de siège et procédé de construction | |
| EP3668496A4 (fr) | Inhibiteurs d'ahr et leurs utilisations | |
| EP3735427A4 (fr) | Anticorps anti-mct1 et utilisations associées | |
| EP3890028A4 (fr) | Panneau d'affichage et terminal | |
| EP3481952A4 (fr) | Marqueurs de méthylation dans le traitement de la leucémie et leurs utilisations | |
| DE112017007289A5 (de) | Selbstnivellierendes möbelstück und betriebsverfahren | |
| EP3976630A4 (fr) | Protéines de liaison à actrii et leurs utilisations | |
| EP3697265A4 (fr) | Siège de déplacement et de découverte | |
| EP3717007C0 (fr) | Antagonistes de l'ildr2 et associations correspondantes | |
| EP3856755A4 (fr) | Dérivés de terpinoïdes et leurs utilisations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20200715 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40037571 Country of ref document: HK |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20220208 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/69 20170101ALI20220202BHEP Ipc: A61K 47/64 20170101ALI20220202BHEP Ipc: A61P 35/00 20060101ALI20220202BHEP Ipc: C07K 16/28 20060101ALI20220202BHEP Ipc: C07D 475/04 20060101ALI20220202BHEP Ipc: A61K 31/519 20060101AFI20220202BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20230818 |